The estimated Net Worth of Bret Scholtes is at least 1.82 百万$ dollars as of 30 August 2021. Mr Scholtes owns over 10,000 units of Guardion Health Sciences Inc stock worth over 1,816,378$ and over the last 8 years he sold GHSI stock worth over 0$.
Sign up
Mr Scholtes GHSI stock SEC Form 4 insiders trading
Mr has made over 1 trades of the Guardion Health Sciences Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of GHSI stock worth 12,400$ on 30 August 2021.
The largest trade he's ever made was buying 10,000 units of Guardion Health Sciences Inc stock on 30 August 2021 worth over 12,400$. On average, Mr trades about 1,111 units every 0 days since 2017. As of 30 August 2021 he still owns at least 179,484 units of Guardion Health Sciences Inc stock.
You can see the complete history of Mr Scholtes stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Bret D. Scholtes biography
Bret D. Scholtes is the Pres, CEO & Director at Guardion Health Sciences Inc.
How old is Mr Scholtes?
Mr Scholtes is 51, he's been the Pres、 CEO & Director of Guardion Health Sciences Inc since . There are 5 older and 1 younger executives at Guardion Health Sciences Inc. The oldest executive at Guardion Health Sciences Inc is Robert Neal Weingarten, 69, who is the Independent Chairman & Sec..
What's Mr Scholtes's mailing address?
Bret's mailing address filed with the SEC is C/O GUARDION HEALTH SCIENCES, INC., 2925 RICHMOND AVENUE, SUITE 1200, HOUSTON, TX, 77098.
Insiders trading at Guardion Health Sciences Inc
Over the last 6 years, insiders at Guardion Health Sciences Inc have traded over 1,626,803$ worth of Guardion Health Sciences Inc stock and bought 131,721 units worth 845,035$ . The most active insiders traders include Bradley Louis Radoff Family...、Andrew C Schmidt、Bret Scholtes. On average, Guardion Health Sciences Inc executives and independent directors trade stock every 273 days with the average trade being worth of 625,568$. The most recent stock trade was executed by Bradley Louis Radoff Family... on 26 August 2024, trading 115,540 units of GHSI stock currently worth 1,626,803$.
What does Guardion Health Sciences Inc do?
by applying the latest science, technology and research, guardion health sciences (ghs) has positioned itself to address the escalating demand for solutions that promise to improve life-diminishing health problems facing the aging baby boomer generation. guardion health sciences is dedicated to applying a scientific discipline and pharmaceutical approach to the development of safe, standardized and effective condition specific solutions. using the individual and collective knowledge of the members of our science advisory board, we will advise healthcare professionals and the public on the importance of medical foods and nutrition to achieve overall good health. the company’s first medical food, lumega-z, is scientifically formulated to restore and maintain the macular protective pigment. a depleted macular pigment is a known contributor to amd. though lumega-z was created with the amd epidemic in mind, its ingredients are also thought to be beneficial for other types of eye disease (i.
What does Guardion Health Sciences Inc's logo look like?
Complete history of Mr Scholtes stock trades at Guardion Health Sciences Inc
Guardion Health Sciences Inc executives and stock owners
Guardion Health Sciences Inc executives and other stock owners filed with the SEC include:
-
Dr. David W. Evans MBA, Ph.D.,
Chief Scientific Officer & Director -
Robert Neal Weingarten,
Independent Chairman & Sec. -
Dr. David W. Evans,
Chief Scientific Officer & Director -
Craig J. Sheehan,
Chief Commercial Officer -
Jeffrey Benjamin,
Chief Accounting Officer -
Andrew C. Schmidt,
VP & CFO -
Bret D. Scholtes,
Pres, CEO & Director -
Donald A Gagliano,
Director -
Mark Goldstone,
Director -
Robert N Weingarten,
Director -
Bradley Louis Radoff Family...,
-
Kelly Anderson,
Director -
David W Evans,
Chief Scientific Officer -
Michael Favish,
Chief Executive Officer -
Craig Sheehan,
Chief Commercial Officer -
Bret Scholtes,
CEO and President -
Michaela Griggs,
Director -
Janet Hall,
CEO & President